AC Immune (ACIU) Net Equity Issued and Repurchased (2015 - 2025)

AC Immune (ACIU) has reported Net Equity Issued and Repurchased for 11 consecutive years, with -$1251.2 the latest figure, recorded in Q4 2025.

• In Q4 2025, Net Equity Issued and Repurchased changed N/A year-over-year to -$1251.2; the TTM figure through Dec 2025 stood at $7893.4 (changed 0.31% YoY), while the FY2025 annual figure was $7236.8, down 9.43% from the prior year.
• Net Equity Issued and Repurchased retreated to -$1251.2 in Q4 2025 per ACIU's latest filing, from $6250.5 in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $4.7 million in Q4 2021 and bottomed at -$13272.7 in Q1 2021.
• Historically, Net Equity Issued and Repurchased has averaged $282575.1 across 5 years, with a median of $3357.3 in 2024.
• Annual changes were most pronounced in 2021 — Net Equity Issued and Repurchased soared 8881.88% — and 2023, when it sank 699.09%.
• AC Immune's Net Equity Issued and Repurchased stood at $4.7 million in 2021, then tumbled by 99.98% to $1035.5 in 2022, then soared by 444.38% to $5636.8 in 2023, then sank by 79.52% to $1154.2 in 2024, then slumped by 208.4% to -$1251.2 in 2025.
• Business Quant data shows ACIU's Net Equity Issued and Repurchased at -$1251.2 in Q4 2025, $6250.5 in Q3 2025, and $8455.2 in Q2 2025.